By Associate Professor Megan Amanda Crumbaker

Conference Abstracts

Joshua AM; Talmor B; Crumbaker M; Yam AO; Ng CA; Luckett T, 2026, 'Determining individual preferences for gynecomastia avoidance among men with prostate cancer: A qualitative study.', in Journal of Clinical Oncology, Vol. 44, pp. TPS407 - TPS407, http://dx.doi.org/10.1200/JCO.2026.44.7_suppl.TPS407

Emmett L; Kwan EM; Joshua AM; Sharma S; Hioki T; Sandhu S; Crumbaker M, 2026, 'Dose optimisation and PSMA receptor intensification with 177Lu-PSMA-597 in metastatic castration-resistant prostate cancer (mCRPC): The randomised phase II OPTIMAL-PSMA trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 44, pp. tps293 - tps293, http://dx.doi.org/10.1200/jco.2026.44.7_suppl.tps293

Hansen AR; Goh JC; Pattison DA; Ngai S; Gan CLL; Katchel L; Brady J; Kuchel A; Latter M; Mason R; Santoro P; Crumbaker M; Baronet MC; Grace R; Brilhante J; Kryza T; Kuan K; Wiegert E; Karmann A; Wyld D, 2026, 'Phase 2 expansion study of 212Pb-ADVC001 in metastatic prostate cancer: The TheraPb trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 44, pp. tps280 - tps280, http://dx.doi.org/10.1200/jco.2026.44.7_suppl.tps280

Hall A; Crumbaker M; Pham J; Liu J; Sim HW; Joshua AM, 2024, 'A meta-analysis of overall survival and response in metastatic adrenocortical carcinoma: A review of 23 prospective trials of 880 patients.', in Journal of Clinical Oncology, Vol. 42, pp. 4 - 4, http://dx.doi.org/10.1200/JCO.2024.42.4_suppl.4

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of ¹⁷⁷Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Kumar AR; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5027 - 5027, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5027

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Kumar AR; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5017 - 5017, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5017

Emmett L; Subramaniam S; Martin AJ; Zhang AY; Yip S; Crumbaker M; Rana N; Francis RJ; Hofman MS; Joshua AM; Sandhu SK; Azad A; Gedye C; Weickhardt AJ; Goh JC; Ng S; Voskoboynik M; McJannett MM; Stockler MR; Davis ID; Group AANZUAPCT, 2022, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. tps205 - tps205, http://dx.doi.org/10.1200/jco.2022.40.6_suppl.tps205

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Niman R; Wilson P; Sharma S; Ayers M; Eu P; Stockler MR; Martin AJ; Joshua AM; Emmett L, 2022, 'Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 177LuPSMA-617 and NOX66 (LuPIN).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 166 - 166, http://dx.doi.org/10.1200/jco.2022.40.6_suppl.166

Lau B; Crumbaker M; Yam AOW; Marastoni S; Luckhurst M; O'Grady A; Wouters B; Joshua AM, 2021, 'A phase I/II study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): Dose escalation results.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 39, pp. 114 - 114, http://dx.doi.org/10.1200/jco.2021.39.6_suppl.114

Emmett L; Subramaniam S; Zhang AY; Martin AJ; Yip S; Crumbaker M; Rana N; Ford K; Langford A; Francis RJ; Hofman MS; Joshua AM; Sandhu SK; Azad A; Gedye C; McJannett MM; Stockler MR; Davis ID, 2021, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 39, pp. tps177 - tps177, http://dx.doi.org/10.1200/jco.2021.39.6_suppl.tps177

Pathmanandavel S; Crumbaker M; Yam AOW; Rofe C; Ho B; Chan WL; Sharma S; Hickey AJ; Kongrak K; Ratnayake L; Kwan EM; Azad A; Eu P; Nguyen A; Joshua AM; Emmett L, 2021, 'Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 39, pp. 103 - 103, http://dx.doi.org/10.1200/jco.2021.39.6_suppl.103

Sandhu SK; Joshua AM; Emmett L; Spain L; Horvath LG; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Kumar AR; Alipour R; Akhurst T; Kong G; Davis ID; Williams S; Hicks R; Hofman M, 2021, '577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', in Annals of Oncology, Elsevier, Vol. 32, pp. s626 - s627, http://dx.doi.org/10.1016/j.annonc.2021.08.1090

Ardolino L; Tang R; Pathmanandavel S; Crumbaker M; Joshua A; Emmett L, 2019, 'Lu-177-PSMA-617 as monotherapy or in combination with NOX66 for the treatment of men with late-stage metastatic castrate resistant prostate cancer (mCRPC): An exploratory analysis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 115 - 115, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400147&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Crumbaker M; Nguyen A; Ho B; Yin C; Isheish N; Azad A; Violet J; Sharma S; Joshua A, 2019, 'Interim results of a Phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and NOX66 in men with mCRPC post androgen signalling inhibition and 2 lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, CA, Anaheim, Vol. 60, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), CA, Anaheim, 22 June 2019 - 25 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473116800464&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Chen J; Joshua AM; Denmeade SR; Antonarakis ES; Crumbaker M, 2019, 'High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, pp. tps5095 - tps5095, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.tps5095

Back to profile page